LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Closed

Sector Healthcare

235.05 -1.04

Buy Sell

Overview

Share price change

24h

Current

Min

232.81

Max

239.66

Key metrics
By Trading Economics
Income	72M -66M
Sales	55M 494M
EPS	-0.16
Profit margin	-13.338
Employees	2,100
EBITDA	100M -2.8M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+13.06 upside

Dividends
By Dow Jones
Next Earnings	1 Aug 2024

Market Stats
By TradingEconomics
Market Cap	2.2B 33B
Previous open	236.09
Previous close	235.05

News Sentiment

By Acuity

37%

63%

81 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

234.16 / 235.3 Support & Resistance

Alnylam Pharmaceuticals Inc Chart

Related News

26 Jul 2024, 22:06 UTC

Major Market Movers

vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study

26 Jul 2024, 19:26 UTC

Earnings

Trending: 3M Shares Surge On Earnings

26 Jul 2024, 17:40 UTC

Earnings

Merck KGaA FY24 Outlook Improves After Strong Second Quarter

26 Jul 2024, 17:21 UTC

Major Market Movers

Aon Shares Rise Following Better-Than-Expected 2Q Results

26 Jul 2024, 22:40 UTC

Acquisitions, Mergers, Takeovers

Burger King Parent Company and More Stocks See Action From Activist Investors -- Barrons.com

26 Jul 2024, 21:27 UTC

Market Talk

Consumers Are Skipping Starbucks' Half-Priced Drinks -- Market Talk

26 Jul 2024, 20:54 UTC

Earnings

3M Stock Had Its Best Day Ever. The New CEO Started With a Bang. -- Barrons.com

26 Jul 2024, 20:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

26 Jul 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 Jul 2024, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

26 Jul 2024, 20:50 UTC

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc Forecast

Price Target

By TipRanks

13.06% upside

12 Months Forecast

Average 268.95 USD 13.06%

High 400 USD

Low 159 USD

Based on 20 Wall Street analysts offering 12 month price targets forAlnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Alnylam Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

234.16 / 235.3Support & Resistance

Bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

81 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.